Persson H, Rythe'n-Alder E, Melcher A, Erhardt L
Section of Cardiology, Karolinska Institute, Danderyd Hospital, Sweden.
Br Heart J. 1995 Aug;74(2):140-8. doi: 10.1136/hrt.74.2.140.
To evaluate whether xamoterol, a partial agonist, would improve exercise time more than metoprolol in patients with mild to moderate heart failure after a myocardial infarction.
Single-centre double blind randomised parallel group comparison of metoprolol 50-100 mg and xamoterol 100-200 mg twice daily.
210 patients aged 40-80 years (173 men) with clinical evidence of heart failure early after a myocardial infarction. 106 were given metoprolol and 104 xamoterol.
Exercise test results and performance at three months; the exercise test, quality of life, and clinical assessments at baseline (5-7 days after the infarction) and after 3, 6, and 12 months.
Exercise time increased at three months by 22% in the metoprolol group and 29% in the xamoterol group, but with no significant difference between the groups. Patients taking xamoterol showed overall non-significantly higher mean values of exercise time achieved with higher heart rates at rest and exercise. Improvements in quality of life, clinical signs of heart failure, and New York Heart Association functional class were seen in both treatment groups over one year, with minor benefits of xamoterol on breathlessness, peripheral oedema, and functional class. Eighteen patients taking metoprolol and 22 taking xamoterol withdrew from the study during one year, with a low mortality, reinfarction rate, and progress of heart failure in both treatment groups. Mean dose from baseline to 3 months was 135 mg metoprolol and 347 mg xamoterol.
beta 1 Receptor antagonists with or without partial agonist activity are safe to use in mild to moderate heart failure after a myocardial infarction. Exercise tolerance, quality of life, and clinical signs and functional class of heart failure improve, and few patients show deterioration in their condition. Exercise tolerance is no better with xamoterol than metoprolol.
评估部分激动剂扎莫特罗是否比美托洛尔更能改善心肌梗死后轻至中度心力衰竭患者的运动时间。
单中心双盲随机平行组比较,每日两次服用50 - 100毫克美托洛尔和100 - 200毫克扎莫特罗。
210名年龄在40 - 80岁之间的患者(173名男性),有心肌梗死后早期心力衰竭的临床证据。106名患者服用美托洛尔,104名患者服用扎莫特罗。
三个月时的运动测试结果和表现;基线(心肌梗死后5 - 7天)以及3、6和12个月后的运动测试、生活质量和临床评估。
美托洛尔组三个月时运动时间增加了22%,扎莫特罗组增加了29%,但两组之间无显著差异。服用扎莫特罗的患者在静息和运动时心率较高时达到的运动时间总体平均值略高,但无显著差异。两个治疗组在一年中生活质量、心力衰竭临床体征和纽约心脏协会功能分级均有改善,扎莫特罗在呼吸困难、外周水肿和功能分级方面有轻微益处。一年中,18名服用美托洛尔的患者和22名服用扎莫特罗的患者退出研究,两个治疗组的死亡率、再梗死率和心力衰竭进展均较低。从基线到3个月的平均剂量,美托洛尔为135毫克,扎莫特罗为347毫克。
具有或不具有部分激动剂活性的β1受体拮抗剂在心肌梗死后轻至中度心力衰竭中使用是安全的。运动耐量、生活质量以及心力衰竭的临床体征和功能分级均有改善,很少有患者病情恶化。扎莫特罗的运动耐量并不比美托洛尔更好。